PhRMA: HRSA’s Pushback Against Drug Maker Policies Permits Program Exploitation

The brand drug lobby is calling on Congress to pass legislation that would demand more transparency from hospitals and community health centers participating in the 340B drug discount program and curb statutory violations following the government’s success in getting Johnson & Johnson to cease implementation of a policy that would have paid a rebate to certain covered entities for select 340B drugs instead of the traditional upfront discount.